Mu opioid receptors gate locus coeruleus pain
Analysis based on 6 articles · First reported Aug 17, 2026 · Last updated Sep 06, 2026
The discovery could spur development of more targeted chronic pain treatments, potentially reducing reliance on systemic opioids and their side effects. This may benefit biotech and pharma companies focused on pain management, though clinical application remains years away.
Researchers at Washington University School of Medicine in St. Louis identified that mu opioid receptors in the locus coeruleus, a brain region involved in stress and alertness, act as a biological brake on chronic neuropathic pain. In mouse models, nerve injury flips this region into a pain generator, but restoring these receptors reversed hypersensitivity. The findings, published in Current Biology on August 17, 2026, suggest targeted therapies could relieve chronic pain with fewer opioid side effects. The study was led by Jordan McCall and co-first authors Emperor Renzong of Song and Makenzie R. Norris, and funded by the United States — National Institutes of Health, United States — National Science Foundation, Rita Allen Foundation, and Coefficient Giving.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard